synbiotic and hypothyroidism
- Conditions
- Hypothyroidism.Hypothyroidism, unspecified
- Registration Number
- IRCT20121216011763N35
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 56
Age of 18 to 65 years
Hypothyroid patients with a history of treatment for more than one year using levothyroxine (sodium)
TSH is at least one year with a constant dose of levothyroxine in the normal range
No smoking and alcohol
Non pregnant, non-lactating
Non-use of drugs that affect metabolism and absorption of levothyroxine include: iron sulfate, magnesium sulfate, warfarin, luvastatin, amiodarone, sumatropin, calcium carbonate, orlistat, multivitamin and minerals, theophylline, ritunavir, rifampin, phenytoin, karmazapine, Phenobarbital, Sucralfate, Aluminum hydroxide, Sertraline, Bile doses, Estrogens and other estrogen modifying drugs, Proton pump suppressants, Phosphate binders
People who, after explaining the work, were willing to cooperate and answer questions and conduct experiments
Thyroid cancer
Intestinal malabsorption (history of obstructive surgery, inflammatory bowel disease, celiac disease)
Antibiotic use
Acute and chronic infectious diseases
Use of drugs that affect the absorption and metabolism of levothyroxine, including (iron sulfate, magnesium sulfate, warfarin, luvastatin, amiodarone, sumatropin, calcium carbonate, orlistat, multivitaminomineral, theophylline, ritunavir, rifampin, Tween, Karmazpine, Phenobarbital, Sucralfate, Aluminum Hydroxide, Sertraline, Bile Drug, Estrogen and other estrogen modifying drugs, proton pump inhibitor drugs, phosphate binders)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Thyroid-stimulating hormone. Timepoint: Before the start of the study and 8 weeks after the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA).;Free triiodothyronine (FT3). Timepoint: Before the start of the study and 8 weeks after the intervention. Method of measurement: enzyme-linked immunosorbent assay (ELISA).
- Secondary Outcome Measures
Name Time Method